132 related articles for article (PubMed ID: 14597979)
1. The antiaggregating activity of clopidogrel is not affected by N-acetyl L-cysteine.
Lalé A; Herbert JM; Savi P
Thromb Haemost; 2003 Nov; 90(5):839-43. PubMed ID: 14597979
[TBL] [Abstract][Full Text] [Related]
2. P2Y12, a new platelet ADP receptor, target of clopidogrel.
Herbert JM; Savi P
Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
[TBL] [Abstract][Full Text] [Related]
3. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
Savi P; Herbert JM
Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
Niitsu Y; Jakubowski JA; Sugidachi A; Asai F
Semin Thromb Hemost; 2005 Apr; 31(2):184-94. PubMed ID: 15852222
[TBL] [Abstract][Full Text] [Related]
5. Identification and biological activity of the active metabolite of clopidogrel.
Savi P; Pereillo JM; Uzabiaga MF; Combalbert J; Picard C; Maffrand JP; Pascal M; Herbert JM
Thromb Haemost; 2000 Nov; 84(5):891-6. PubMed ID: 11127873
[TBL] [Abstract][Full Text] [Related]
6. Effect of clopidogrel administration to healthy volunteers on platelet phosphorylation events triggered by ADP.
Contreres JO; Dupuy E; Job B; Habib A; Bryckaert M; Rosa JP; Simoneau G; Herbert JM; Savi P; Levy-Toledano S
Br J Haematol; 2003 Feb; 120(4):633-42. PubMed ID: 12588350
[TBL] [Abstract][Full Text] [Related]
7. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel.
Hechler B; Eckly A; Ohlmann P; Cazenave JP; Gachet C
Br J Haematol; 1998 Dec; 103(3):858-66. PubMed ID: 9858246
[TBL] [Abstract][Full Text] [Related]
8. Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy.
Bal Dit Sollier C; Berge N; Boval B; Hovsepian L; Drouet L
Thromb Haemost; 2009 Jan; 101(1):116-22. PubMed ID: 19132197
[TBL] [Abstract][Full Text] [Related]
9. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors.
Gachet C; Cattaneo M; Ohlmann P; Hechler B; Lecchi A; Chevalier J; Cassel D; Mannucci PM; Cazenave JP
Br J Haematol; 1995 Oct; 91(2):434-44. PubMed ID: 8547091
[TBL] [Abstract][Full Text] [Related]
10. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
[TBL] [Abstract][Full Text] [Related]
11. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
[TBL] [Abstract][Full Text] [Related]
12. Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study.
Campbell CL; Berger PB; Nuttall GA; Orford JL; Santrach PJ; Oliver WC; Ereth MH; Thompson CM; Murphy MK; McGlassen DL; Schrader LM; Steinhubl SR
Am Heart J; 2005 Oct; 150(4):796-9. PubMed ID: 16209984
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1.
Fox SC; Behan MW; Heptinstall S
Cell Calcium; 2004 Jan; 35(1):39-46. PubMed ID: 14670370
[TBL] [Abstract][Full Text] [Related]
14. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
[TBL] [Abstract][Full Text] [Related]
15. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
Diehl P; Olivier C; Halscheid C; Helbing T; Bode C; Moser M
Basic Res Cardiol; 2010 May; 105(3):379-87. PubMed ID: 19943165
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of clopidogrel resistance.
Almsherqi ZA; McLachlan C; Mossop PJ; Deng Y
Thromb Res; 2005; 116(5):451-3. PubMed ID: 16039696
[No Abstract] [Full Text] [Related]
17. A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models.
Wang YX; Vincelette J; da Cunha V; Martin-McNulty B; Mallari C; Fitch RM; Alexander S; Islam I; Buckman BO; Yuan S; Post JM; Subramanyam B; Vergona R; Sullivan ME; Dole WP; Morser J; Bryant J
Thromb Haemost; 2007 May; 97(5):847-55. PubMed ID: 17479197
[TBL] [Abstract][Full Text] [Related]
18. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of clopidogrel after administration of a high loading dose.
Taubert D; Kastrati A; Harlfinger S; Gorchakova O; Lazar A; von Beckerath N; Schömig A; Schömig E
Thromb Haemost; 2004 Aug; 92(2):311-6. PubMed ID: 15269827
[TBL] [Abstract][Full Text] [Related]
20. Biomarker optimization to track the antithrombotic and hemostatic effects of clopidogrel in rats.
Schumacher WA; Bostwick JS; Ogletree ML; Stewart AB; Steinbacher TE; Hua J; Price LA; Wong PC; Rehfuss RP
J Pharmacol Exp Ther; 2007 Jul; 322(1):369-77. PubMed ID: 17420297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
